Studying immune response in patients receiving CAR-T cell therapy
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how your immune system responds to CAR-T cell therapy, a treatment that uses your own immune cells to fight certain cancers. By participating, you help researchers learn more about how this therapy affects the body, which could improve care for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You are scheduled to receive CAR-T cell therapy as part of your regular treatment.
- You are not pregnant or breastfeeding.
- You are covered by French social security.
- You are willing to sign a consent form to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects and stores biological samples from people who have been treated with CAR-T cells at the University Hospital of Montpellier. Your samples can help researchers learn more about treatment effects and safety.
This study looks at a biological process called trogocytosis (when immune cells swap pieces of their outer coating) to see if it can help predict how well CAR-T cell therapy works for people with a type of lymphoma called diffuse large B-cell lymphoma.
This study looks at blood samples from people with blood cancers to find markers that might predict how well immunotherapy will work. The goal is to help doctors choose the right treatment for each person.
This study looks at how patients with blood cancers are managed in real life when they receive CAR-T cell therapy. It helps doctors learn more about how well these treatments work outside of clinical trials.
This study looks at how your immune system responds after you receive CAR-T cell therapy for multiple myeloma. The goal is to learn more about the treatment's effects and how well it works.
This study collects health data from people in France who received CAR-T treatment or are eligible to receive it. It helps doctors and researchers understand who can get CAR-T and how treatment is used in real life.
Hear when a new Hematologic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.